Deepali Mishra

Dr. Deepali Mishra

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Oncology Research
Verified
Journal Article
Open access
PDF file
DNDhanya K. Nambiar
Dhanya K. Nambiar
DMDeepali Mishra
Deepali Mishra
RSRana Pratap Singh
Rana Pratap Singh
Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical applications. We focused on the use of PARP inhibitors in various cancers, including prostate cancer. We also discussed some of the underlying principles and challenges that may affect the clinical efficacy of PARP inhibitors.

24 November 2022 in The FASEB Journal
Verified
Journal Article
Closed access
Akash SabarwalAkash Sabarwal
Akash Sabarwal
JRJaco C. van Rooyen
Jaco C. van Rooyen
JCJeremy Caburet
Jeremy Caburet
MAMoscos Avgenikos
Moscos Avgenikos
ADArpit Dheeraj
Arpit Dheeraj
RSRana Pratap Singh
Rana Pratap Singh

30 September 2022 in Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MRMohit Rajput
Mohit Rajput
DMDeepali Mishra
Deepali Mishra
KKKunal Kumar
Kunal Kumar
RSRana Pratap Singh
Rana Pratap Singh
Mohit Rajput, Deepali Mishra, Kunal Kumar, Rana P. Singh. J Cancer Prev 2022;27:170-81. https://doi.org/10.15430/JCP.2022.27.3.170

1 October 2024 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MAMansoor Ali
Mansoor Ali
DMDeepali Mishra
Deepali Mishra
RSRana Pratap Singh
Rana Pratap Singh
: Cancer is a complex and heterogeneous malignant disease. Due to its multifactorial nature, including progressive changes in genetic, epigenetic, transcript, and protein levels, conventional therapeutics fail to save cancer patients. Evidence indicates that dysregulation of microRNA (miRNA) expression plays a crucial role in tumorigenesis, metastasis, cell proliferation, differentiation, metabolism, and signaling pathways. Moreover, miRNAs can be used as diagnostic and prognostic markers and therapeutic targets in cancer. Berberine, a naturally occurring plant alkaloid, has a wide spectrum of biological activities in different types of cancers. Inhibition of cell proliferation, metastasis, migration, invasion, and angiogenesis, as well as induction of cell cycle arrest and apoptosis in cancer cells, is reported by berberine. Recent studies suggested that berberine regulates many oncogenic and tumor suppressor miRNAs implicated in different phases of cancer. This review discussed how berberine inhibits cancer growth and propagation and regulates miRNAs in cancer cells. And how berberine-mediated miRNA regulation changes the landscape of transcripts and proteins that promote or suppress cancer progression. Overall, the underlying molecular pathways altered by berberine and miRNA influencing the tumor pathophysiology will enhance our understanding to combat the malignancy.

5 August 2025 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
NSNavneendra Singh
Navneendra Singh
MAMansoor Ali
Mansoor Ali
PBPriyanka Biswal
Priyanka Biswal
AJAishwarya Jaiswal
Aishwarya Jaiswal
DMDeepali Mishra
Deepali Mishra
RSRana Pratap Singh
Rana Pratap Singh

12 December 2025 in Cell Communication and Signaling
Verified
Journal Article
Open access
JPJyoti Pandey
Jyoti Pandey
ZMZubbair Malik
Zubbair Malik
RSRitis K. Shyanti
Ritis K. Shyanti
PPPalak Parashar
Palak Parashar
PKPraveen K. Kujur
Praveen K. Kujur
RSRana Pratap Singh
Rana Pratap Singh
Head and neck squamous cell carcinoma (HNSCC) exhibits substantial genetic and functional heterogeneities. We generated clonal spheroids (CS) from HNSCC cell lines and patient tumor cells, uncovering distinct functional differences. Hyperproliferative spheroids (HRPS) showed increased proliferation and tumorigenic potential, whereas hypoproliferative spheroids (HOPS) demonstrated enhanced migration and resistance to cisplatin and radiation. In patient tumor-derived spheroids, spheroid size distribution analysis across various TNM stages indicated that early-stage tumors (T2N0M0) predominantly formed HRPS, while later-stage tumors (T4N2M0) exhibited a higher prevalence of HOPS. Single-cell RNA sequencing (scRNA-seq) identified six clusters in the HOPS and four in the HRPS, each defined by unique gene expression profiles and pathway enrichment. HOPS were enriched with fibroblast, mesenchymal, and keratinizing epithelial cells, indicating a metastatic phenotype. They also expressed genes associated with stemness (KRT15 and ALDH3A1). Conversely, HRPS was characterized by proliferative genes, including TOP2A, AURKA, CKS2, AREG, and ANLN, suggesting an advanced HNSCC proliferative signature. Despite being generated from only two cells/well, the various clusters in both spheroid types mirrored the diverse tumor microenvironment in HNSCC, including neoplastic, epithelial, basal, fibroblast, and mesenchymal cells. Notably, the gene expression profiles of Cluster 3 in the HOPS and Cluster 1 in the HRPS closely matched the expression patterns observed in the HNSCC-TCGA dataset. These clusters also displayed a high transcriptional correlation between patient tumors and their xenografts, reinforcing the clonal nature of HNSCC's genetic and functional diversity of HNSCC.